In this video, Motley Fool analysts and editors David Williamson and Andrew Tonner sit down and catch up on how the week treated health-care stocks.
In this edition, four biotech companies dominated the news. There was a positive FDA panel vote, but most of it centered around three critical trial results -- results that can be best described using the famed "the good, the bad, and the ugly" moniker. We highlight key takeaways from each event and lend our opinion on what investors should be looking at going forward.
To see which biotechs soared and which stocks cratered, click on the video below.
Looking for our prediction for 2012? Check out The Motley Fool's brand-new report, "The Motley Fool's Top Stock for 2012." It highlights a company that's revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.
At the time thisarticle was published David Williamsonand Andrew Tonner own no shares in any company mentioned.Click hereto see David Williamson's holdings and a short bio.Motley Fool newsletter serviceshave recommended buying shares of Gilead Sciences. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.